The brief

Analyst view

• Founded June 2024; Laura Deming (CEO) and Hunter Davis (CSO). $58M Series A Sept 2025 for organ cryopreservation.
• The Series A was led by Founders Fund with participation from Lux Capital and Field Ventures.
• Sept 2024 progress report showed electrical activity recovery in rewarmed rodent neural tissue.

Technical approach

As reported

Vitrification

Glass, not ice

Cooling to –130°C solidifies water as amorphous glass, not ice crystals. Ice crystals rupture cell membranes; glass preserves structure.

Five dimensions

The engineering problem

Perfusion (filling organ with cryoprotectant), cryoprotectants, cooling rates, rewarming without damage, and viability assays.

Magnetic rewarming

No hot fluid needed

Alternating magnetic fields with nanoparticles generate uniform heat throughout the organ, avoiding temperature gradients that cause damage.